MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

×

Message d'erreur

  • Notice : Undefined property: stdClass::$ds_changed dans eval() (ligne 16 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$ss_search_api_url dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$tm_title dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$ds_changed dans eval() (ligne 16 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$ss_search_api_url dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$tm_title dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).

Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Mercredi, juin 21, 2023
Information
Tags: 
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, GFR, Hyperkalemia, Carcinoma, Radiation, Nephrotoxicity, Biodistribution, Blood urea nitrogen, Dosimetry, Half-life, Creatinine, Overalls, Quality of life, Glomerular filtration rate, NET, Dicarboxylic acid, Vomiting, Serum albumin, MD, Patient, Cancer, Kidney, Creatine, Nausea, BUN, PRRT, Phosphorus, Dietary supplement, Safety
Geotags: 
PENNSYLVANIA, UNITED STATES, NORTH AMERICA
⚠ partially generated by AI ↴
Organisation: 
MOLECULAR TARGETING TECHNOLOGIES, MOLECULAR TARGETING TECHNOLOGIES, INC.
Résumé
Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.
  • A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia.
  • EBTATE administration appears to be safe without amino acid infusion.”
    Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs.
  • Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion.


Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment. EBTATE’s safety, biodistribution, and dosimetry in a crossover randomized protocol in patients (N=10) with and without amino acids were published in Clinical Nuclear Medicine.1

The kidney is sensitive to radiation. Peptide receptor radionuclide therapy (PRRT) dosing is constrained by potential kidney toxicity. A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia. The Evans blue moiety in EBTATE binds to serum albumin, extending in vivo circulatory half-life and residence time, reducing renal uptake and hence making amino acid infusion unnecessary.

Professor Zhaohui Zhu, MD, principal investigator, commented, “Our results showed that administration of EBTATE without amino acid infusion had acceptable kidney radiation absorbed dose and residence time. One month after EBTATE, there were no significant changes in creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR). None of the patients had nephrotoxicity of any grade. Furthermore, a recent one-year follow-up showed creatine and BUN of all patients stayed within normal limits. EBTATE administration appears to be safe without amino acid infusion.”

Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs. The benefits of EBTATE treatment without amino acids are clear. We expect EBTATE trials in small cell lung cancer, NET, and nasopharyngeal cancers to show the same benefit.”

Molecular Targeting Technologies, Inc. (MTTI). MTTI is a privately held, venture-backed, clinical-stage biotech company developing next-generation targeted radiotherapeutics for rare cancers with high unmet needs. MTTI is committed to building value by translating innovative radiopharmaceuticals to improve human health and reduce healthcare costs. MTTI is orchestrating multiple clinical trials. For more information: www.evathera.com; Contact: Chris Pak, Email: [email protected]

* Jiang Y, Liu Q, Wang G, et al. . Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion. Clin Nucl Med 18 Apr 2023, 48(6):e289-e293

Copyright: 
Copyright Business Wire 2023